Navigation Links
Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived,,,Tissue

In situ Adapter for the RoboCycler 40 Temperature Cycler allows rapid amplification of rare mRNA

Donald D. Lorimer * Robert E. Carroll * Richard V. Benya
Department of Medicine, University of Illinois at Chicago

In situ adapter system for the RoboCycler 40 temperature cycler is designed for holding standard microscope slides.

Reverse transcriptase in situ PCR (RTISPCR) is a recently described method for detecting mRNAs in archival paraffin tissue blocks. This method is readily performed using the RoboCycler 40 Temperature Cycler# and its microscope slide attachment, the in situ Adapter for the RoboCycler 40 Temperature Cycler. In this article, we describe our RTISPCR method for detecting the rare message for the gastrin-releasing peptide (GRP) receptor expressed by a previously resected gastrointestinal tract tumor. By detecting mRNAs in tissues that have been maintained in paraffin blocks and archived for over 50 years, this technology promises to dramatically expand the use of PCR amplification.

The GRP receptor is a member of the 7-transmembranespanning, G protein-coupled receptor superfamily. Within the gastrointestinal (GI) tract, GRP receptors are normally expressed by smooth muscle cells and by nerve endings, acting to regulate intestinal motility and to induce the secretion of other enteric peptide hormones.1-3 However, GRP receptors are not expressed by mucosal epithelial cells lining the normal GI tract in the few mammals studied, including dogs4 and humans.5 In contrast, recent studies have shown that GRP receptors are aberrantly expressed by a number of human colon cancers6 and colon cancer cell lines including HT29, MC2
'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. Tools for Detecting MSH2 Expression in Chinese Hamster Ovary Cells
2. Two-dimensional Optimization of a Semi-nested PCR for Detecting Listeria monocytogenes
3. Detecting miRNA & siRNA
4. Detecting Attomole Amounts of Small RNA
5. Structural Analysis of Glycosylated Peptides in Complex Mixtures with Ion Trap MSn
6. Efficient Primary Structure Elucidation of Disulfide-bridged Peptides
7. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
8. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
9. Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer
10. Separation of Peptides by Hydrophilic Interaction Chromatography Using TSKgel Amide-80
11. LC-MALDI and MALDI-MS/MS for the Analysis of Complex Peptide Mixtures

Post Your Comments:
(Date:11/20/2009)... , SEATTLE, Nov. 20 /PRNewswire-FirstCall/ ...CTIC) announced today that the Ninth Circuit Court...nd ruled that CTI should be allowed to pursue all ...case back to the District Court for trial. CTI fi...er third-party reimbursement consultant for CTI,s ...
(Date:11/19/2009)... , SEATTLE, Nov. 19 O... unaudited financial results for the third quarter...ded September 30, 2009, Omeros reported a net loss...to a net loss of $7.4 million, or $2.54 per share,...ended September 30, 2009, the Company reported a n...
(Date:11/19/2009)... , MALVERN, Pa. and WALTHAM, Mass., Nov. 19... and Decision Resources find that the leading driv... in Europe is broad-spectrum activity against gram...variety of organisms that can cause nosocomial pne...hey look primarily for agents that provide appropr...
(Date:11/19/2009)... InSound is honored by latest ... Newark, CA (PRWEB) November 16, 2009...ldquo;invisible” hearing aid from InSound Me... New Award in the Health category.  &nbs...s designed to reside deep in the hearing canal for...
Breaking Biology Technology:Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
...e Corporation, a,Georgia-based biotech company, to...sory Board (SAB) to collaborate on the development...and guide future therapeutic,and diagnostic projec...tific founder Richard Meagher, PhD, Chief,Scientif...essor at the,University of Georgia, and inventor o...
...simo (Nasdaq:,MASI), the inventor of Pulse CO-Oxim...pulse oximetry, today announced,that all customers...agship,product, will now receive Desat Index 3D Al...imeters typically alarm based on large and,isolate...esaturation".,However, published research has show...
...ABB accreditation bolsters PCT,s commitment to qua... distribution. , Hackensa... Therapy, LLC (PCT) announced today that it has ob... Blood Activities - Processing, Storage, Distribut...oactive to 1 April 2008 after satisfactorily passi...
Other Biology Technology:Abeome Forms First Class Scientific Advisory Board 2Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices 2Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices 3Progenitor Cell Therapy Secures Industry Accreditation 2Progenitor Cell Therapy Secures Industry Accreditation 3Progenitor Cell Therapy Secures Industry Accreditation 4
(Date:11/19/2009)...the genetic instructions inside corn, one of the b...the most complex sequences of DNA ever analyzed, s...id Schwartz, who was one of more than 100 authors ...maize genome is a true maze full of confusing rep...uencers for years," says Schwartz. , Publication...
(Date:11/19/2009)...he offspring of two inbred strains tend to be supe...gene-level variability that leads to this phenomen...t our ability to custom-tailor crops for specific ...sumption or high glucose content for biomass fuel....ce of the common corn strain B73, University of Mi...
(Date:11/19/2009)...aize, also known as corn, researchers across the U...d pave the way to significant improvements in a pl...eed and fiber around the world. , The new map, a..., charts genetic diversity and recombination acros...arch team, led by U.S. Department of Agriculture s...
Breaking Biology News(10 mins):Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 1Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 2Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 3Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 4Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 5Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 6Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference 14843 1Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference 14843 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 1Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 3
... is a hereditary blood disease, primarily affectin...entially life-threatening ,bleeds,. About one in 6...evere, moderate or mild form. People with haemophi...ctor VIII clotting protein. , Professor Denisa Wag...eaking discoveries that provide hope of an alterna...
... have discovered that tumors release fatty acids t...ll them. Consequently, strategies that reduce the ...ive a boost to anti-cancer therapeutics. The detai... of the Journal of Lipid Research, an American Soc...l. , Several forms of anti-cancer therapy rely on ...
...enomic researchers headed by biologists at New Yor...enomics, in collaboration with researchers at Harv...x Biosciences, has mapped out a preliminary molecu...n, offering for the first time a global look at ho...lar organism. The findings are reported in the Aug...
Other Biology News:Promising therapies for haemophilia & heart disease 2Researchers discover new tumor defense system 2NYU biologists map out early stages of embryo formation 2
Sheep Anti-11-DEOXY-CORTICOSTERONE (-OCMO) Polyclonal Antibody, Unconjugated from AbD Serotec
Equine Immunoglobulin G from Equitech-Bio
Mouse Anti-Human IFN-Gamma RC2 (CD118) Non-Neutralizing Monoclonal Antibody, Unconjugated, Clone MMHGR-2 from PBL InterferonSource
Rat CINC-2 beta, Unconjugated from R&D Systems
Biology Products: